This article has Open Peer Review reports available.
A seven-year disease-free survivor of malignant pleural mesothelioma treated with hyperthermia and chemotherapy: a case report
© Okonogi et al.; licensee BioMed Central Ltd. 2012
Received: 4 May 2012
Accepted: 16 November 2012
Published: 28 December 2012
Malignant pleural mesothelioma was once a rare finding but its incidence is increasing worldwide, most likely because of widespread exposure to asbestos. Although complete surgical resection is considered the only curative treatment, the results of surgery have shown a median survival time of only one year. In inoperable cases, chemotherapy, radiotherapy, and a combination of both have been considered as palliative therapy. Therefore, outcomes for inoperable cases have been poor. Here, we report the case of a long-term survivor treated with hyperthermia and chemotherapy.
A 61-year-old Japanese man with a performance status of 1 due to chest pain was referred to our hospital. He had a history of asbestos exposure for approximately five years. A computed tomography scan showed diffuse extensive right pleural thickening with small nodular lesions, and video-assisted thoracoscopy revealed tumor invasion of the ipsilateral chest wall muscles. The histopathologic findings were consistent with a diagnosis of malignant pleural mesothelioma (sarcomatoid type). The tumor was diagnosed as being stage cT3N0M0. Our patient refused any invasive therapies including surgery and radiotherapy, and was therefore treated with hyperthermia and systemic chemotherapy with agents such as cisplatin and irinotecan. He underwent three hyperthermia sessions and a single course of chemotherapy without any severe complications. One month after treatment, a follow-up computed tomography scan showed no definitive abnormality in the thoracic space. Our patient has subsequently survived without any evident disease for more than seven years.
The combination of hyperthermia and chemotherapy may be a novel and safe therapeutic option for malignant pleural mesothelioma, and can be considered for patients ineligible for radical treatment. Further clinical studies of the combination of hyperthermia and chemotherapy are needed to confirm the effects of this treatment on malignant pleural mesothelioma.
Malignant pleural mesothelioma (MPM) was once a rare finding, but its incidence is increasing worldwide, most likely because of widespread exposure to asbestos [1, 2]. MPM is considered to have a poor prognosis, and complete surgical resection is the only curative treatment. However, the post-operative median survival time (MST) after surgery is only approximately one year [3–5]. Moreover, there is no standard treatment for inoperable MPM. We report a case of a seven-year disease-free survivor who was diagnosed as having MPM and was treated with hyperthermia and chemotherapy.
Our patient was eligible for surgery; however, he refused any invasive therapies such as surgery and radiotherapy. Therefore, we proposed systemic chemotherapy with hyperthermia, which was used by our institution at that time for unresectable lung cancers with or without malignant pleural effusion [4, 5]. Our patient agreed to this treatment strategy; he provided his written informed consent after a comprehensive discussion regarding the nature of his illness and standard therapeutic options, including surgery and combined modality therapy. Three weeks after the biopsy, systemic chemotherapy with hyperthermia was administered once a week. The chemotherapy regimen included cisplatin 60mg/m2 (100mg/body) on day one and irinotecan 60mg/m2 (100mg/body) on days one, eight, and 15. Hyperthermia was performed using a radiofrequency (RF)-capacitive heating apparatus (Thermotron-RF 8; Yamamoto Vinita Co. Ltd., Osaka, Japan) once a week (on days one, eight, and 15) for approximately 60 minutes immediately after irinotecan administration. The electrodes measured 30cm in diameter and were placed in front of and behind our patient to heat the entire thoracic cavity. A pair of overlay boluses were used to prevent any edge effect and for cooling the surface of the body. Thermosimulation revealed that the nodular lesions were approximately 42.5°C and the right pleural thickening >40°C.
MPM develops after asbestos exposure and has a long latency period. Its incidence is currently increasing worldwide because of the extent of asbestos exposure between the years 1965 and 1980 [1, 2]. MPM has a poor prognosis, mainly because of its inherent resistance to conventional treatment. Therefore, it is necessary to identify novel treatment strategies.
Radical surgical resection is considered the only curative treatment; however, the post-operative MST for such patients is only approximately 12 months. The benefits of such an aggressive approach have been questioned because the treatment-related mortality rate is 7.0 percent to 11.5 percent [6–8]. Recently, trimodality therapies such as combinations of surgical resection and chemoradiotherapy for operable MPM cases have improved the prognosis [9–11]. Flores et al. reported a MST of 19 months for operable MPM , and Perrot et al. reported a five-year overall survival rate of 10 percent following trimodality treatment. However, the rate of treatment-related mortality remains high, and is equivalent to approximately 5 percent of all patients who undergo trimodality treatments [9, 10]. Additionally, the rate of treatment-related morbidities such as atrial arrhythmias, respiratory failure, and pneumonia, among others, is 25 percent to 55 percent [9–11]. These complications can reduce a patient’s quality of life.
Moreover, chemotherapy, radiotherapy, or a combination of both have been considered as palliative therapy in inoperable cases. Over the past two decades, a number of single-agent and combination chemotherapy studies have been performed for MPM. Unfortunately, all the published reviews have reported poor response rates of approximately 30 percent, and a short MST of approximately 10 months [12, 13]. In a recent study, Vogelzang et al. reported that MST for subjects in the pemetrexed/cisplatin arm was 12.1 months, whereas that for subjects in the cisplatin monotherapy arm was 9.3 months . However, this result is still not a satisfactory one.
Cisplatin-based conventional chemotherapy regimens and their efficacy against malignant pleural mesothelioma
Admissions interval (median courses)
Number of patients
Median survival (months)
Cisplatin (75mg/m2 on day one)/pemetrexed (500mg/m2 on day one)
Every three weeks, 6.0 courses
Cisplatin (60mg/m2 on day one)/irinotecan (60mg/m2 on days one, eight, and 15)
Every four weeks, 2.6 courses
Cisplatin (100mg/m2 on day one)/vinblastine (6mg/m2 on days one and eight)
Every four weeks, 4.0 courses
Cisplatin (60mg/m2 on day 1)/doxorubicin (60mg/m2 on day one)
Every three to four weeks, 3.0 to 4.0 courses
Cisplatin (100mg/m2 on day one)/gemcitabine (1000mg/m2 on days one, eight, and 15)
Every four weeks, 4.0 courses
Cisplatin (60mg/m2 on day one)/irinotecan (60mg/m2 on days one, eight, and 15)
One course with hyperthermia
Hyperthermia is known to be directly cytotoxic to cancer cells [19–21]. When cells are exposed to elevated temperatures, damage is inflicted at multiple sites; the predominant molecular target appears to be proteins such as heat shock proteins (HSPs) . Roth et al. reported the effects of heat stress on HSPs . It was noted that hyperthermia induced the downregulation heat-stress-induced Hsp40 and Hsp70 expression and reduced the survival of mesothelioma cells.
Some clinical reports have also reported the benefits of hyperthermia. Matsuzaki et al. reported on intra-pleural chemotherapy perfusion with hyperthermia to induce MPM cell apoptosis. MPM cells obtained from pleural effusions showed apoptotic action, peaking at 24 hours after perfusion . Xia et al. reported significant prolongation of MST by hyperthermia combined with intra-thoracic chemotherapy and radiotherapy for MPM. Although a complete response was not achieved, MST was 27.1 months without any severe side effects . These reports suggest that hyperthermia may have a special effect on MPM cells, and that the combination of hyperthermia and chemotherapy may act synergistically.
This report describes a rare case of a long-term survivor with MPM. Our patient has been disease-free for more than seven years without any complications. The combination of hyperthermia and chemotherapy may be a novel and safe therapeutic option for MPM and can be considered in cases ineligible for radical treatment. Further clinical studies of the hyperthermia-chemotherapy combination are required to confirm its effects on MPM.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the consent form is available for review by the Editor-in-Chief of this journal.
We would like to thank Dr Takaaki Sano and Dr Aya Suzuki (pathologists) as well as Dr Kimihiro Shimizu (thoracic surgeon) of Gunma University for their valuable support.
- Wagner JC, Sleggs CA, Marchand P: Diffuse pleural mesothelioma. Br J Ind Med. 1960, 17: 260-271.PubMedPubMed CentralGoogle Scholar
- Kishimoto T, Ozaki S, Kato K, Nishi H, Genba K: Malignant pleural mesothelioma in parts of Japan in relationship to asbestos exposure. Ind Health. 2004, 42: 435-439. 10.2486/indhealth.42.435.View ArticlePubMedGoogle Scholar
- Welker L, Müller M, Holz O, Vollmer E, Magnussen H, Jörres RA: Cytological diagnosis of malignant mesothelioma–improvement by additional analysis of hyaluronic acid in pleural effusions. Virchows Arch. 2007, 450: 455-461. 10.1007/s00428-007-0375-x.View ArticlePubMedGoogle Scholar
- Ishikawa H, Nakayama Y, Sakurai H, Kitamoto Y, Nonaka T, Kiyohara H, Shioya M, Wakatsuki M, Kawamura H, Hasegawa M, Nakano T: Challenge of hyperthermia combined with chemotherapy or chemo-radiotherapy for unresectable intrathotacic malignant tumors: a preliminary result. Jpn J Hyperthermic Oncol. 2005, 21: 159-169.Google Scholar
- Ebara T, Sakurai H, Wakatsuki M, Nonaka T, Ishikawa H, Kawamura H, Yoshida D, Shioya M, Nakayama Y, Nakano T: Inoperable Pancoast tumors treated with hyperthermia-inclusive multimodality therapies. Lung Cancer. 2009, 63: 247-250. 10.1016/j.lungcan.2008.05.023.View ArticlePubMedGoogle Scholar
- Rusch VW, Rosenzweig K, Venkatraman E, Leon L, Raben A, Harrison L, Bains MS, Downey RJ, Ginsberg RJ: A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001, 122: 788-795. 10.1067/mtc.2001.116560.View ArticlePubMedGoogle Scholar
- Flores RM, Pass HI, Seshan VE, Dycoco J, Zakowski M, Carbone M, Bains MS, Rusch VW: Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008, 135: 620-626. 10.1016/j.jtcvs.2007.10.054.View ArticlePubMedGoogle Scholar
- Schipper PH, Nichols FC, Thomse KM, Deschamps C, Cassivi SD, Allen MS, Pairolero PC: Malignant pleural mesothelioma: surgical management in 285 patients. Ann Thorac Surg. 2008, 85: 257-264. 10.1016/j.athoracsur.2007.06.066.View ArticlePubMedGoogle Scholar
- Batirel HF, Metintas M, Caglar HB, Yildizeli B, Lacin T, Bostanci K, Akgul AG, Evman S, Yuksel M: Trimodality treatment of malignant pleural mesothelioma. J Thorac Oncol. 2008, 3: 499-504. 10.1097/JTO.0b013e31816fca1b.View ArticlePubMedGoogle Scholar
- de Perrot M, Feld R, Cho BC, Bezjak A, Anraku M, Burkes R, Roberts H, Tsao MS, Leighl N, Keshavjee S, Johnston MR: Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol. 2009, 27: 1413-1418. 10.1200/JCO.2008.17.5604.View ArticlePubMedGoogle Scholar
- Flores RM, Krug LM, Rosenzweig KE, Venkatraman E, Vincent A, Heelan R, Akhurst T, Rusch VW: Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol. 2006, 1: 289-295. 10.1097/01243894-200605000-00004.View ArticlePubMedGoogle Scholar
- Steele JP, Klabatsa A: Chemotherapy options and new advances in malignant pleural mesothelioma. Ann Oncol. 2005, 16: 345-351. 10.1093/annonc/mdi094.View ArticlePubMedGoogle Scholar
- Janne PA: Chemotherapy for malignant pleural mesothelioma. Clin Lung Cancer. 2003, 5: 98-106. 10.3816/CLC.2003.n.023.View ArticlePubMedGoogle Scholar
- Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003, 21: 2636-2644. 10.1200/JCO.2003.11.136.View ArticlePubMedGoogle Scholar
- Nakano T, Chahinian AP, Shinjo M, Togawa N, Tonomura A, Miyake M, Ninomiya K, Yamamoto T, Higashino K: Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile. Cancer. 1999, 85: 2375-2384. 10.1002/(SICI)1097-0142(19990601)85:11<2375::AID-CNCR12>3.0.CO;2-E.View ArticlePubMedGoogle Scholar
- Tsavaris N, Mylonakis N, Karvounis N, Bacoyiannis C, Briasoulis E, Skarlos D, Pavlidis N, Stamatelos G, Kosmidis P: Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma. Lung Cancer. 1994, 11: 299-303. 10.1016/0169-5002(94)90550-9.View ArticlePubMedGoogle Scholar
- Ardizzoni A, Rosso R, Salvati F, Fusco V, Cinquegrana A, De Palma M, Serrano J, Pennucci MC, Soresi E, Crippa M: Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study. Cancer. 1991, 67: 2984-2987. 10.1002/1097-0142(19910615)67:12<2984::AID-CNCR2820671208>3.0.CO;2-Q.View ArticlePubMedGoogle Scholar
- Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D, Mitchell P, Musk AW, Robinson BW: A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer. 2002, 87: 491-496. 10.1038/sj.bjc.6600505.View ArticlePubMedPubMed CentralGoogle Scholar
- Dewey WC, Hopwood LE, Sapareto SA, Gerweck LE: Cellular response to combinations of hyperthermia and radiation. Radiology. 1977, 123: 463-474.View ArticlePubMedGoogle Scholar
- Suit HD, Gerweck LE: Potential for hyperthermia and radiation therapy. Cancer Res. 1979, 39: 2290-2298.PubMedGoogle Scholar
- Roizin-Towle L, Pirro JP: The response of human and rodent cells to hyperthermia. Int J Radiat Oncol Biol Phys. 1991, 20: 751-756. 10.1016/0360-3016(91)90018-Y.View ArticlePubMedGoogle Scholar
- Richter K, Haslbeck M, Buchner J: The heat shock response: life on the verge of death. Mol Cell. 2010, 40: 253-266. 10.1016/j.molcel.2010.10.006.View ArticlePubMedGoogle Scholar
- Roth M, Zhong J, Tamm M, Szilard J: Mesothelioma cells escape heat stress by upregulating Hsp40/Hsp70 expression via mitogen-activated protein kinases. J Biomed Biotechnol. 2009, 2009: 451084-View ArticlePubMedPubMed CentralGoogle Scholar
- Matsuzaki Y, Tomita M, Shimizu T, Hara M, Ayabe T, Onitsuka T: Induction of apoptosis by intrapleural perfusion hyperthermo-chemotherapy for malignant pleural mesothelioma. Ann Thorac Cardiovasc Surg. 2008, 14: 161-165.PubMedGoogle Scholar
- Xia H, Karasawa K, Hanyu N, Chang TC, Okamoto M, Kiguchi Y, Kawakami M, Itazawa T: Hyperthermia combined with intra-thoracic chemotherapy and radiotherapy for malignant pleural mesothelioma. Int J Hyperthermia. 2006, 22: 613-621. 10.1080/02656730601012508.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.